New Oncology and Gustave Roussy announce collaboration on genetic testing
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
List view / Grid view
News
Rigontec GmbH raises €9.45m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
ABPI and OBN announce Memorandum of Understanding
13 October 2014 | By ABPI and OBN
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding...
Horizon Discovery Group plc acquires Sage Labs Inc. for $48M (£29M)
13 October 2014 | By Horizon Discovery Group
Horizon Discovery Group plc announced it has agreed to acquire Sage Labs Inc. (Sage) for up to $16M (£9.8M) in cash and up to $32M (£19.6M) through the issue of new ordinary shares...
Advanced Cell Diagnostics awarded $1.4 million NCI Grant to develop ultrasensitive diagnostic test for B-cell lymphoma
10 October 2014 | By Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. has been awarded a two-year, $1.4 million grant from National Cancer Institute under its SBIR Phase II Program...
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb’s novel immunotherapy in combination treatments for NSCLC
9 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab)...
New study shows UK public are largely unaware of stem cells as the potential uses are still being realised
9 October 2014 | By On Broadcast
18 years since the first cord blood transplants were performed in the UK, public knowledge on this life-saving process is still sorely lacking. A study of over 4,000 people found that nearly a third (32%) of Britons did not know you can store umbilical cord blood and tissue, while the…
Bristol-Myers Squibb announces collaboration to evaluate Opdivo (nivolumab) in combination with targeted therapies from Novartis to treat non-small cell lung cancer
8 October 2014 | By Bristol-Myers Squibb Company
Studies will evaluate Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Novartis’ Zykadia (ceritinib), INC280 and EGF816...
Merck Serono to collaborate with The Institute of Cancer Research, London, and Wellcome Trust to co-develop anti-cancer drugs
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
OBN celebrates the stars of UK Life Sciences
3 October 2014 | By OBN
OBN revealed last night the winners of its Annual Awards celebrating the best of UK life sciences – the innovators, fundraisers and dealmakers who underline the pre-eminence of the UK sector in the global marketplace...
Event preview: Drug Discovery Week Europe
3 October 2014 | By GTCbio
From 7-10 October 2014, GTCbio will proudly present its Drug Discovery Week Europe event in the beautiful city of Dublin, Ireland...
Allied-Bristol Life Sciences appoints Satish Jindal to lead the discovery of drug candidates from leading academic institutions
3 October 2014 | By Allied-Bristol Life Sciences
Allied-Bristol Life Sciences today announced that Satish Jindal, Ph.D., formerly Vice President of R&D within Bristol-Myers, has been appointed to lead the company’s efforts to identify and foster development of biopharmaceutical innovations from top U.S. university research institutions...
Thermo Scientific TGA-IR Module enhances materials characterization for users of Thermo Scientific FT-IR Spectrometers
1 October 2014 | By Thermo Fisher Scientific
Scientists involved in materials characterization, process validation and product failure analysis can gather more valuable data by combining two powerful analytical techniques...
Cardio3 BioSciences announces new business development strategy to broaden its product pipeline
1 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases...
Avacta Life Sciences takes on the $55bn antibody market with launch of Affimers
1 October 2014 | By Avacta Life Sciences
Avacta Life Sciences is investing £10m in the launch of Affimers, the engineered alternative to antibodies...
